Findings show integration of a promoterless CAR at the TRAC locus enables physiologic CAR expression and durable anti-tumor activity in preclinical models The research further describes optimization ...
Findings show integration of a promoterless CAR at the TRAC locus enables physiologic CAR expression and durable anti-tumor activity in preclinical models BERKELEY, Calif., March 18, 2026 (GLOBE ...
Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platform Peer-reviewed publication demonstrates stable, cell-specific transgene expression ...
Findings show integration of a promoterless CAR at the TRAC locus enables physiologic CAR expression and durable anti-tumor activity in preclinical models ...
In vivo platform enables efficient, site-specific CAR gene insertion under control of an endogenous T cell promoter, producing functional CAR T cells inside the body Single dose administration in ...
BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced new preclinical data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results